-
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading cross-functional teams Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, who will continue to serve as President of Biologics Lonza today announced that its Board of Directors has approved the appointment of Daniel Palmacci as President of its Cell & Gene Division. The appointment will be effective from 1 November 2022. Daniel takes over the role from Jean-Christophe Hyvert, who continues to serve as President of Lonza’s…
-
Lonza and Touchlight collaborate on end-to-end mRNA offering
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM) Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability Customers can gain access to Touchlight’s dbDNA as an integral part of Lonza’s offering, benefiting from end-to-end mRNA manufacturing capabilities to expedite time to market Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced a collaboration with Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution. Through this collaboration, Lonza will have the ability to integrate an additional, differentiated source of DNA…
-
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a margin of 33.1% H1 2022 CAPEX reached 28.2% of sales as Lonza continues to execute planned investments Group Outlook 2022 confirmed at low to mid-teens CER sales growth and CORE EBITDA margin improvement Mid-Term Guidance 2024 reconfirmed Lonza has reported sales of CHF 3 billion, growing 17.3% AER2 (16.8%1 CER) and CHF 987 million CORE EBITDA, resulting in a margin of 33.1%. Thanks to the commitment of colleagues across Lonza’s global network, the company has successfully navigated the challenges arising from the uncertain macroeconomic environment in the First Half. Lonza…
-
Maria Soler Nunez appointed as Head, Group Operations
. Lonza appoints Maria Soler Nunez as Head, Group Operations Maria joins Lonza from Novartis where she has led the quality organization since 2020 Maria will commence her tenure with Lonza Group on 1 August 2022, succeeding Stefan Stoffel, who is retiring from Lonza Lonza today announced that its Board of Directors has appointed Maria Soler Nunez as the new Head, Group Operations. The appointment will be effective from 1 August 2022. Maria will succeed Stefan Stoffel as a member of the Lonza Group Executive Committee. Maria joins Lonza Group from Novartis where she has worked since 2010, holding a succession of leadership positions in quality and operations. In her…
-
Grand Opening of Kodiak Sciences‘ Purpose-Built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
. Purpose-built bioconjugation facility in Lonza’s Ibex® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak’s lead product candidate KSI-301 for high-prevalence retinal diseases The opening ceremony took place on May 17, 2022 following mechanical completion of the facility in March 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, and Lonza announced today the opening of a new, custom-built, bioconjugation facility within Lonza’s Ibex® Dedicate manufacturing complex in Visp (CH). The facility will play a key role in the scaled manufacturing of Kodiak’s lead therapeutic candidate KSI-301 to support a potential…
-
Lonza Announces Results of the 2022 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Shareholders re-elected all existing members of the Board of Directors who stood for re-election and elected Marion Helmes and Roger Nitsch as new members of the Board of Directors Albert M. Baehny was re-elected as Chairman of the Board of Directors for another year A dividend of CHF 3.00 per share will be paid out starting from 11 May 2022 33,179,173 shareholders delegated their votes to the independent proxy, representing 45% of the share capital Board of Directors to initiate audit tender in Q2 2022 for services starting from the financial year 2024 Today, Lonza Group Ltd hosted its Annual General Meeting (AGM), led by the Chairman of the Board…
-
Lonza Publishes Invitation to the 2022 Annual General Meeting and 2021 Annual and Sustainability Reports
. Annual General Meeting to take place on 5 May 2022 at the company’s headquarters in Basel, Switzerland Albert M. Baehny proposed for re-election as Chairman of the Board of Directors Stable dividend of CHF 3.00 per share proposed 2021 Annual and Sustainability Reports published Lonza today announced the publication of its 2021 Annual and Sustainability Reports, as well as its invitation to the 2022 Annual General Meeting (AGM). The event will take place on Thursday, 5 May 2022, at 10:00 a.m. CEST, at the company’s headquarters in Muenchensteinerstrasse 38, 4002 Basel, Switzerland. To consider the health and safety of Lonza’s shareholders and employees, and in line with the applicable…
-
Christian Seufert appointed as President of Capsules and Health Ingredients Division
. Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses He will commence his tenure with Lonza Group on 1 July 2022 Christian succeeds Claude Dartiguelongue who retires from Lonza on 31 July 2022 Lonza today announced that its Board of Directors has appointed Christian Seufert as President of Capsules and Health Ingredients Division. The appointment will be effective from 1 July 2022. Christian will succeed Claude Dartiguelongue as a member of the Lonza Group Executive Committee. Christian joins Lonza Group from BASF,…
-
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk)
Lonza erzielt einen Umsatz von CHF 5.4 Milliarden und einem Umsatzwachstum von 20% (kWk)1 CHF 1.7 Milliarden Kern-EBITDA resultieren in einer Marge von 30,8% 2021 erreichten die Investitionsausgaben 24% des Umsatzes und unterstützten den langfristigen Plan durch risikoarme Wachstumsinvestitionen attraktive Margen zu erzielen Weiterhin Konzentration auf operative Spitzenleistungen und die Durchführung von Wachstumsprojekten Ausblick für 2022: Umsatzwachstum (kWk) im unteren bis mittleren Zehnerbereich und Verbesserung der Kern-EBITDA-Marge im Einklang mit der mittelfristigen Prognose für 2024 Mittelfristige Prognose für 2024 bestätigt Lonza hat einen Umsatz von CHF 5,4 Milliarden mit einem Wachstum von 20% AER (20% kWk) und CHF 1,7 Milliarden Kern-EBITDA berichtet, was einer Marge von 30,8% entspricht. Diese starke…
-
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth
Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8% 2021 CAPEX reached 24% of sales, supporting long-term plan to deliver attractive margins through de-risked growth investments Continuing focus on operational excellence and execution of growth projects Outlook 2022: low to mid-teens CER sales growth and CORE EBITDA margin improvement in line with 2024 Mid-Term Guidance Mid-Term Guidance 2024 reconfirmed Lonza has reported sales of CHF 5.4 billion, growing 20% AER (20% CER) and CHF 1.7 billion CORE EBITDA, resulting in a margin of 30.8%. This strong momentum at Group level was driven by sales growth ahead of market…
